Clinical Trial Update: A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and pharmacokinetics of BCX4430 in filovirus infections, including Ebola virus disease, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease
• Filovirus Infections

Drugs mentioned

• BCX4430

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Filovirus Infections, Ebola Virus Infection | Phase 1 | Status: COMPLETED